Myelodysplastic Syndrome (MDS)

- Lower-Risk
- Intermediate
  - IRB# 16338 Aileron Phase 1/1b ALRN-6924 (Wild Type TP53)
  - IRB# 16964 FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)
  - IRB# 18352 Astex study – ASTX727 vs IV Decitabine
  - IRB# 17379 Novartis Phase 1B PDR001 and/or MBG453 with decitabine
- High Risk
  - New MDS
    - IRB# 16867 Abbvie 531 phase 1b venetoclax + azacitidine in treatment naive subjects
  - Relapsed/Refractory
    - IRB# 16964 FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)
    - IRB# 16338 Aileron Phase 1/1b ALRN-6924 (Wild Type TP53)
    - IRB# 17379 Novartis Phase 1B PDR001 and/or MBG453 with decitabine
    - IRB# 16984 Abbvie 522 venetoclax by itself or in combination with azacitidine in relapsed/refractory subjects
  - Treatment Related
    - IRB# 15993 HLA-A2.0 and PRAME (relapsed/refractory MDS)

CMML

- IRB# 18352 Astex study – ASTX727 vs IV Decitabine
- IRB# 18809 Study coming soon

Studies coming soon
IRB# 18809
IRB# 19290

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php